Exciting research news!!! Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, announced that the results from a compassionate use patient case study using NO to treat pulmonary Mycobacterium abscessus disease (M. abscessus disease) at the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, was published in a scientific article, “Antibacterial Activity of High-dose Nitric Oxide against Pulmonary Mycobacterium abscessus Disease” in the August 2020 edition of Access Microbiology, a peer-reviewed journal published by the Microbiology Society.

Read More